Regarding “new method to create a vascular arteriovenous fistula in the arm with an endoscopic technique”  by Dammers, Ruben & Tordoir, Jan H.M.
LETTERS TO THE EDITOR
Regarding “The Carotid Surgery for Ischemic Stroke
trial”
Dr Eckstein and colleagues are to be congratulated on the
results of their prospective observational multicenter trial on the
safety of carotid endarterectomy (CEA) after a nondisabling isch-
emic stroke.1 From March 1997 to August 2000, a remarkable 164
patients experiencing nondisabling stroke underwent CEA within
the first 6 weeks of onset of the neurologic event. The perioperative
stroke and mortality rate was 6.7% (11 of 164 patients), with a
crude perioperative stroke rate of 6.1% (10 of 164 patients). On the
basis of these findings, the authors concluded that early CEA,
within 6 weeks after a related ischemic stroke, carries perioperative
mortality and stroke rates comparable to those reported in con-
trolled multicenter randomized trials.2,3
We recently looked at this issue, prospectively comparing
perioperative outcome between patients with a carotid lesion and
ipsilateral nondisabling stroke who underwent early CEA, ie,
within 30 days, or delayed CEA, ie, more than 30 days after the
neurologic event.4 Over 48 months, all patients who had a non-
disabling ischemic stroke and were referred to our section and
scheduled for elective CEA were invited to take part in a prospec-
tive randomized early versus delayed CEA protocol. Of the 92
patients who met inclusion criteria, 86 agreed to the randomiza-
tion protocol and 6 refused. Forty-five patients were randomized
to receive CEA within 30 days of stroke (median, 18 days; range,
15-30 days), and 41 patients were to receive CEA more than 30
days after stroke (median, 59 days; range, 38-120 days). No
perioperative deaths occurred in either group. Perioperative stroke
incidence was comparable in the two groups (1 of 45 patients [2%]
vs 1 of 41 patients [2%]; both strokes were ipsilateral to the side
operated on and occurred within the first 12 hours of CEA, and
both were minor. No new stroke occurred during the waiting
period in the delayed group, nor were there any late strokes in
either group. No patients had perioperative cerebral hemorrhage,
the most feared complication of early CEA, confirming that this
catastrophic event is rare after early CEA. Both neurologic events
were probably the outcome of small embolisms occurring during
carotid dissection or coming from the endarterectomized site
when blood flow was restored, bearing no relationship to timing of
surgery. This finding correlates closely with that reported by Eck-
stein et al,1 showing that even in this patient population the most
common cause of perioperative failure is technical error and can
thus be averted by improving the technical aspects of the surgical
procedure.5 The study by Eckstein and colleagues, like our own,
provides further evidence that timing of surgery does not influence
benefit of CEA in this patient population. There are also several
considerations, mentioned in the medical literature, that might
well tip the balance in favor of early CEA, ie, risk for recurrent
stroke during the waiting period, complications of interval warfarin
sodium therapy or other special regimens, interruption of physical
therapy programs, and, last, the huge stress engendered in some
patients by the waiting period.
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Regarding “New method to create a vascular
arteriovenous fistula in the arm with an endoscopic
technique”
We read with interest the technical article by Hayakawa et al,1
who describe a minimally invasive technique for harvesting the
upper arm basilic vein for creation of vascular access. This tech-
nique is similar to endoscopic harvesting of the saphenous vein in
the leg for use in peripheral arterial and coronary artery bypass
grafting.2,3 Hayakawa and colleagues report 10 patients who re-
ceived treatment with this endoscopic technique with a commer-
cially available device, with satisfying results. Such video-assisted
endoscopic techniques may be superior to conventional basilic vein
transposition in terms of fewer postoperative complications, eg,
infection, hematoma, seroma formation, and edema, as a result of
extensive skin flap dissection. Moreover, vascular access cannula-
tion may be carried out in an early phase because of improved
wound healing.
The authors raised the suggestion that this technique has not
been described before, as can be established from the listed refer-
ences. However, Martinez et al4 were the first to report on endo-
scopic basilic vein transposition, and we have also reported our
experience.5 In these reports, small series of 9 and 12 patients,
respectively, were operated on with use of various endoscopic
devices to harvest the basilic vein. The outcome in both studies was
similar, with a low incidence of complications and patency ranging
from 75% to 88% after 1 year of follow-up.
Several devices for minimal invasive harvesting are commer-
cially available. Subcutaneous access may be achieved with balloons
introduced and expanded in the subcutaneous tissue with gas
inflation or with expandable devices to create space for dissection
of structures. The Maastricht group developed a custom-made
dissection hook, suitable for introduction of a 5 mm endoscope.
Standard endoscopic instruments were used for vein dissection and
harvesting. In all of our patients, a complete endoscopic technique
was feasible without conversion to open surgical vein harvesting.
The advantages of this new method are obvious: small inci-
sions with less risk for hematoma, edema, and cutaneous nerve
damage. In addition, because of the small incisions, postoperative
pain may be minimal and early cannulation may be possible.
In concordance with Hayakawa and colleagues, we conclude
that video-assisted endoscopic basilic vein transposition is a prom-
ising surgical technique for creation of vascular access in patients
undergoing dialysis.
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Regarding “A prospective study of ultrasound-guided
thrombin injection of femoral pseudoaneurysm: A
trend toward minimal medication”
It is with interest I read the article by Olsen et al.1 Their data
support the findings that lower doses of thrombin are effective for
treatment of femoral pseudoaneurysm, as previously reported by
Reeder et al.2
However, there appear to be troublesome omissions with
regard to their methods. In this prospective study there is no
mention of adherence to the principles of the Declaration of
Helsinki.3 Point 13 of the Declaration states that “The design and
performance of each experimental procedure involving human
subjects should be clearly formulated in an experimental protocol.
This protocol should be submitted for consideration, comment,
guidance, and where appropriate, approval to a specially appointed
ethical review committee, which must be independent of the
investigator, the sponsor or any other kind of undue influence.”
The Journal of Vascular Surgery publication rules stipulate that
“Manuscripts that involve research conducted on human subjects
must follow the principles outlined in the Declaration of Helsinki
and include a statement in the Methods section that the experi-
mental protocol and informed consent were approved by the
institutional review board and that all subjects gave informed
consent.” In the article by Olsen and colleagues, no mention is
made of informed patient consent or of institutional review board
approval, again, required of all studies involving human research.4
Adherence to these rules is mandatory to ensure the highest ethical
standards when conducting biomedical research.
In addition, while exclusion criteria were given, no mention
was made regarding the number of patients excluded from the
study. Did any eligible patients refuse participation in the study?
Were any eligible patients not included in the study for any other
reason?
Prospective study designs require that informed consent be
obtained, institutional review board approval be obtained, and
study end points be defined before patient enrollment in a study.
Olsen and colleagues do not provide enough information in their
article to determine whether these rules were followed. One could
suppose that the patients treated in their study would have been
treated similarly in the absence of a defined protocol, and thus
informed consent for participation in a trial was unnecessary be-
cause their treatment conformed to standard of care. If so, this
study should then be more appropriately called a retrospective
analysis, not a prospective study.
Ashutosh V. Rao, MD
Harvard University School of Medicine
Brigham & Women’s Hospital
Boston, Mass
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Reply
We appreciate your comments, and we hope this will clarify
your concerns. This was not an “experimental procedure involving
human subjects.” This method of treatment of common femoral
pseudoaneurysm is our standard practice, as it is in many other
centers. In our practice, ultrasound-guided thrombin injection is
attempted, and if it is unsuccessful, a second attempt is made. If the
second attempt fails, surgical repair is implemented. Please note
that treatment options including compression, open surgical re-
pair, and thrombin injection were discussed with each patient. In
addition, risks and benefits of each intervention were discussed.
You are correct in stating that the institutional review board
must approve the off-label use of a drug if its use involves human
subjects and you are researching its effect. The board is not
required to review off-label use of a drug if “it is intended to be
solely the practice of medicine,” which it was in our case. This is
our standard practice for treating pseudoaneurysm. As the data
were reviewed, it was evident that less thrombin was necessary to
successfully thrombose a pseudoaneurysm. Perhaps a better pro-
spective study would be to establish a dilution and administer a
single amount, and determine if that would cause thrombosis,
rather than report a trend.
During the study period, 2 patients were considered “outli-
ers.” One patient with a pseudoaneurysm less than 2.0 cm chose
compression therapy. This was successful, but required two inter-
vals of compression. The other patient, with a pseudoaneurysm
greater than 8 cm, underwent successful ultrasound-guided
thrombin injection. This patient would have undergone open
surgical repair if only the size of the pseudoaneurysm was consid-
ered. However, the cardiologist believed she was at high-risk for
anesthesia and surgery. Neither of these patients was included in
the study.
If a prospective study requires that we must establish different
dosing schedules before initiation of the study, rather than pro-
spectively gather data, documenting the dosage used in each case,
then we lack this variable. The data were gathered prospectively
and reviewed retrospectively. We have a database established for
our various procedures. If one of us chose to follow the outcomes
of a procedure, there is the option to retrospectively review previ-
ous cases or begin following up all patients treated during a certain
period. If a prospective study requires that last factor, then you are
correct in deeming this a retrospective study.
Thank you for you comments.
Dawn M. Olsen, PA-C, MMSc
Julio A. Rodriguez, MD
Arizona Heart Institute
Phoenix, Ariz
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